HotPennyStockNews.com is devoted to fetch you the most exclusive stocks in the market today. Apart from scanning the markets for the most underrated stocks. We propel those victors directly to your email inbox first ahead of the rest of the marketplace gets a prospect.
Los Angelas, CA -- (SBWIRE) -- 02/06/2013 -- Zynga Inc (NASDAQ:ZNGA) stock performed well in anticipation of the delivery of this earnings report. On today’s market the company’s shares finished up 7%. Much of the boom in price today may have been due to positive whisper numbers that were being circulated throughout the day.
In the same three months of 2011, the company recorded earnings per share of 4 cents, after some items were removed. In that period the company took in revenues of $311 million. Analysts had expected the company to report a loss of 4 cents per share for the fourth quarter of 2012.
Zynga Inc released several new games in 2012, and much of the subsequent analysis on this earnings report will concentrate on how they performed individually. One of the firm’s biggest releases was Farmville 2. The social game looks to have disappointed in both players and revenue, but there are signs that point to the possibility of a surprise from that sector.
Another important development for the company was the increased attention given to the possibility of earning revenues form online gambling. The company’s Zynga Poker is one of the most enduring titles, and the prospect of monetizing it through legalized gambling is an interesting one. Online poker has, of course, not yet been legalized.
Zynga Inc shares rose to 7.66% to $2.95 in after hours trading.
Is ZNGA a Buy After The recent Pop Up? Find Out Here
Opexa Therapeutics Inc. (NASDAQ:OPXA) is the biggest gainer and soared 185% and made a new 52-week high of $5.19. The stock got a boost on news that the company could get as much as $225M in a commercialization deal struck with Merck for its multiple sclerosis therapy Tcelna. OPXA’s lead product candidate is in Phase IIb trials in patients with secondary progressive MS, and has received FDA fast-track designation. On the other hand Merck gains global development and commercial rights to Tcelna.
Is OPXA a Buy Ahead of Earnings? Find Out Here
Research In Motion Ltd (NASDAQ:BBRY) continued to gain momentum and soared another 8.50% as investors got excited about the company’s launch of Z10 BlackBerry in Canada. The company has been getting very positive feedback from its pre-orders from Canadian and the numbers are yet to be disclosed by the company. RIM and carriers executives say they are encouraged by orders and interest thus far. RIM CEO Thorsten Heins also said early impressions from the U.K., where the Z10 was available last week, are “very, very encouraging.
Is BBRY Showing Any Sign of Buy At The Current Market Price? Find Out Here
Neither HotPennyStockNews.com nor its owners, operators, affiliates or anyone disseminating information on its behalf is registered as an Investment Advisor or broker dealer in any jurisdiction whatsoever and none of the information provided by HotPennyStockNews.com, owners, operators, affiliates or anyone disseminating information on its behalf should be construed as investment advice or an investment recommendation. HotPennyStockNews.com makes no recommendation that the securities of the companies profiled should be purchased, sold or held by individuals or entities that learn of the profiled companies through HotPennyStockNews.com. Investing in securities is speculative and carries a high degree of risk and no investment should be made unless you can afford to lose your entire investment. It is possible that an investor's entire investment may be lost or impaired due to the speculative nature of the companies profiled. Please consult a broker before purchasing or selling any securities viewed on or mentioned herein..
Copyright © 2005-2013 - SBWire, The Small Business Newswire - All Rights Reserved - Important Disclaimer
Contact Us: 888-4-SBWIRE (US) - 920-593-5640 (International)